129 related articles for article (PubMed ID: 19435686)
1. [Tumor Marker CA125: biochemical and molecular properties].
Bouanène H; Miled A
Bull Cancer; 2009 May; 96(5):597-601. PubMed ID: 19435686
[TBL] [Abstract][Full Text] [Related]
2. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
4. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
5. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
6. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
7. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.
Yin BW; Lloyd KO
J Biol Chem; 2001 Jul; 276(29):27371-5. PubMed ID: 11369781
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
10. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
11. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
12. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16.
Bouanene H; Miled A
Dis Markers; 2010; 28(6):385-94. PubMed ID: 20683153
[TBL] [Abstract][Full Text] [Related]
13. CA125/MUC16 is dispensable for mouse development and reproduction.
Cheon DJ; Wang Y; Deng JM; Lu Z; Xiao L; Chen CM; Bast RC; Behringer RR
PLoS One; 2009; 4(3):e4675. PubMed ID: 19262696
[TBL] [Abstract][Full Text] [Related]
14. The cancer antigen CA125 represents a novel counter receptor for galectin-1.
Seelenmeyer C; Wegehingel S; Lechner J; Nickel W
J Cell Sci; 2003 Apr; 116(Pt 7):1305-18. PubMed ID: 12615972
[TBL] [Abstract][Full Text] [Related]
15. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.
Kui Wong N; Easton RL; Panico M; Sutton-Smith M; Morrison JC; Lattanzio FA; Morris HR; Clark GF; Dell A; Patankar MS
J Biol Chem; 2003 Aug; 278(31):28619-34. PubMed ID: 12734200
[TBL] [Abstract][Full Text] [Related]
17. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract][Full Text] [Related]
18. The immunopeptidomic landscape of ovarian carcinomas.
Schuster H; Peper JK; Bösmüller HC; Röhle K; Backert L; Bilich T; Ney B; Löffler MW; Kowalewski DJ; Trautwein N; Rabsteyn A; Engler T; Braun S; Haen SP; Walz JS; Schmid-Horch B; Brucker SY; Wallwiener D; Kohlbacher O; Fend F; Rammensee HG; Stevanović S; Staebler A; Wagner P
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9942-E9951. PubMed ID: 29093164
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
20. [MUC16: The Novel Target for Tumor Therapy].
Gao R; Lou N; Han X; Shi Y
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
